James M Ligon

US Patent:

6346404, Feb 12, 2002

Filed:

May 10, 2000

Appl. No.:

09/568102

Inventors:

Thomas Schupp - Mohlin, CH
James Madison Ligon - Apex NC
Istvan Molnar - Durham NC
Ross Zirkle - Raleigh NC
Devon Dawn Cyr - Fuquay-Varina NC

Assignee:

Novartis AG - Basel

International Classification:

C12N 900

US Classification:

435183, 435232, 435193, 435189, 4352523, 43525235, 4353201, 530350, 536 232, 536 237, 536 231

Abstract:

Nucleic acid molecules are isolated from that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

US Patent:

6355457, Mar 12, 2002

Filed:

May 10, 2000

Appl. No.:

09/567969

Inventors:

Thomas Schupp - Mohlin, CH
James Madison Ligon - Apex NC
Istvan Molnar - Durham NC
Ross Zirkle - Raleigh NC
Devon Dawn Cyr - Fuquay-Varina NC

Assignee:

Novartis AG - Basel

International Classification:

C12N 900

US Classification:

435183, 435189, 435193, 435232, 435195, 435196, 4352523, 43525235, 4353201, 530300, 536 232, 536 231, 536 237

Abstract:

Nucleic acid molecules are isolated from that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

US Patent:

6355458, Mar 12, 2002

Filed:

May 10, 2000

Appl. No.:

09/568480

Inventors:

Thomas Schupp - Mohlin, CH
James Madison Ligon - Apex NC
Istvan Molnar - Durham NC
Ross Zirkle - Raleigh NC
Devon Dawn Cyr - Fuquay-Varina NC

Assignee:

Novartis AG - Basel

International Classification:

C12N 900

US Classification:

435183, 435232, 435193, 435189, 4352523, 43525235, 4353201, 530300, 536 232, 536 237, 536 231

Abstract:

Nucleic acid molecules are isolated from that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

US Patent:

6355459, Mar 12, 2002

Filed:

May 10, 2000

Appl. No.:

09/568486

Inventors:

Thomas Schupp - Mohlin, CH
James Madison Ligon - Apex NC
Istvan Molnar - Durham NC
Ross Zirkle - Raleigh NC
Devon Dawn Cyr - Fuquay-Varina NC

Assignee:

Novartis AG - Basel

International Classification:

C12N 900

US Classification:

435183, 435189, 435193, 435232, 4352523, 43525235, 4353201, 435530, 435300, 435536, 435 232, 435 231, 435 237

Abstract:

Nucleic acid molecules are isolated from that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

US Patent:

6358719, Mar 19, 2002

Filed:

May 10, 2000

Appl. No.:

09/568472

Inventors:

Thomas Schupp - Mohlin, CH
James Madison Ligon - Apex NC
Istvan Molnar - Durham NC
Ross Zirkle - Raleigh NC
Devon Dawn Cyr - Fuquay-Varina NC

Assignee:

Novartis AG - Basel

International Classification:

C12N 902

US Classification:

435189, 4352523, 43525235, 4353201, 536 232, 536 231, 536 237

Abstract:

Nucleic acid molecules are isolated from that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

US Patent:

6383787, May 7, 2002

Filed:

May 10, 2000

Appl. No.:

09/567899

Inventors:

Thomas Schupp - Mohlin, CH
James Madison Ligon - Apex NC
Istvan Molnar - Durham NC
Ross Zirkle - Raleigh NC
Devon Dawn Cyr - Fuquay-Varina NC

Assignee:

Novartis AG - Basel

International Classification:

C12N 900

US Classification:

435183, 435193, 4352523, 43525235, 4353201, 536 232, 536 237, 536 231

Abstract:

Nucleic acid molecules are isolated from that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

US Patent:

6858404, Feb 22, 2005

Filed:

Nov 13, 2001

Appl. No.:

10/014717

Inventors:

Thomas Schupp - Mohlin, CH
James Madison Ligon - Apex NC, US
Istvan Molnar - Durham NC, US
Ross Zirkle - Raleigh NC, US
Devon Dawn Cyr - Fuquay-Varina NC, US
Jörn Görlach - Durham NC, US

Assignee:

Novartis AG - Basel

International Classification:

C12P001/00

US Classification:

435 41, 435 76, 435183, 536 232

Abstract:

Nucleic acid molecules are isolated from that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

US Patent:

20030068788, Apr 10, 2003

Filed:

May 14, 2002

Appl. No.:

10/145415

Inventors:

Thomas Buckel - Freiburg, DE
Philip Hammer - Cary NC, US
Dwight Hill - Cary NC, US
James Ligon - Apex NC, US
Istvan Durham - Durham NC, US
Johannes Pachlatko - Seltisberg, CH
Ross Zirkle - Raleigh NC, US

International Classification:

C12P019/62
C12P021/02
C12N001/21
C12N009/04
C12N009/06
C12N015/74

US Classification:

435/076000, 514/029000, 435/069100, 435/190000, 435/252300, 435/320100, 536/023200, 435/191000

Abstract:

Disclosed is a family of P450 monooxygenases, each member of which regioselectively oxidizes avermectin to 4″-keto-avermectin. The P450 monooxgenases find use in methods and formulations for making emamectin from avermectin. Also disclosed are methods for purifying the P450 monooxygenases of the invention, binding agents that specifically bind to the P450 monooxygenases of the invention, and genetically engineered cells that express the P450 monooxygenases of the invention. Also disclosed are ferredoxins and ferredoxin reductases that are active with the P450 monooxygenases of the invention.